Concert Pharmaceuticals’s Buy Rating Reaffirmed at Roth Capital (CNCE)
Shares of Concert Pharmaceuticals (NASDAQ:CNCE) traded up 1.23% during mid-day trading on Tuesday, hitting $9.455. 96,652 shares of the company’s stock traded hands. Concert Pharmaceuticals has a 52-week low of $7.12 and a 52-week high of $16.26. The stock’s 50-day moving average is $8.97 and its 200-day moving average is $11.10. The company’s market cap is $169.2 million.
Concert Pharmaceuticals (NASDAQ:CNCE) last released its earnings data on Wednesday, May 14th. The company reported ($0.76) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.49) by $0.27. The company had revenue of $1.61 million for the quarter, compared to the consensus estimate of $0.44 million. The company’s quarterly revenue was down 59.0% on a year-over-year basis. Analysts expect that Concert Pharmaceuticals will post $-1.44 EPS for the current fiscal year.
Separately, analysts at Ladenburg Thalmann initiated coverage on shares of Concert Pharmaceuticals in a research note on Thursday, June 26th. They set a “buy” rating and a $24.00 price target on the stock.
Concert Pharmaceuticals Inc is a United States-based company that is engaged in the pharmaceutical preparation and research industry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.